GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Brain cancer vaccine trial aims to stop tumors from returning
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONThis early-phase study tests two mRNA vaccines (GV-108 and GV-907) in 9 adults with a specific type of aggressive brain cancer (IDH-wildtype glioblastoma). The goal is to see if the vaccines are safe and can trigger the immune system to fight the cancer, potentially preventing re…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: EARLY_PHASE1 • Sponsor: Beijing Neurosurgical Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 15, 2026 19:05 UTC
-
Vitamin B3 may boost brain cancer therapy
Disease control TerminatedThis study tests adding high-dose niacin (vitamin B3) to the usual treatment for newly diagnosed glioblastoma, a fast-growing brain cancer. About 59 adults will receive niacin alongside radiation and chemotherapy to see if it is safe and helps delay cancer growth. The goal is to …
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC